Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Park, Sehhoon; Min Kim, Tae; Han, Ji‐Youn; Lee, Gyeong‐Won; Yong Shim, Byoung; Lee, Yun‐Gyoo; Kim, Sang‐We; Hwan Kim, Il; Lee, Suee; Jung Kim, Yu; Hyun Park, Ji; Park, Sang-Gon; Hyeong Lee, Ki; Joo Kang, Eun; Won Kim, Ju; Hoon Shin, Seong; Ock, Chan‐Young; Nam, Byung‐Ho; Lee, Jaebong; Ae Jung, Hyun; Sun, Jong‐Mu; Lee, Se‐Hoon; Seok Ahn, Jin; Ahn, Myung‐Ju

doi:10.1200/jco.23.01891

Public

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Published in Journal of Clinical Oncology • Oct 20, 2023

Authors:

Sehhoon Park

Tae Min Kim

Ji‐Youn Han

Abstract

PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxe...

Subject

Atezolizumab

Medicine

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!